Africa
Data is still coming in from South Africa and other regions about the new Omicron variant of COVID-19. Early analysis suggests it causes less severe disease than other variants.
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
BioNTech plans to increase its manufacturing capacity in Africa over time through the supplementation of new manufacturing lines and construction of additional manufacturing sites.
The Delta variant is the deadliest variant of the coronavirus, and according to the CDC, this variant has the highest transmission rate yet.
GlaxoSmithKline shares jumped in aftermarket trading Wednesday after the WHO recommended broad deployment of the company’s malaria vaccine in sub-Saharan Africa and other areas.
Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results. Craig Rayner, president of Certara, a biosimulation company, is turning to Africa to unlock an untapped reservoir of talent.
PRESS RELEASES